Genetic Mouse Models of Schizophrenia: From Hypothesis-Based To Susceptibility Gene-Based Models

Biological Psychiatry

Volumn 59, Issue 12, 2006, Pages 1180-1188

  Chen, Jingshan ^a   Lipska, Barbara K ^a   Weinberger, Daniel R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

animal; behavior; cognition; genetic; model; Schizophrenia

Indexed keywords

CLOZAPINE; DIZOCILPINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; GLUTAMINE; GUANINE NUCLEOTIDE BINDING PROTEIN; HALOPERIDOL; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEU DIFFERENTIATION FACTOR; NEUROLEPTIC AGENT; PHENCYCLIDINE; PSYCHEDELIC AGENT; TOLCAPONE;

BEHAVIOR DISORDER; COGNITION; DISEASE PREDISPOSITION; DOPAMINERGIC SYSTEM; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC MODEL; GENETIC SUSCEPTIBILITY; HUMAN; NERVE CELL DIFFERENTIATION; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SYMPTOM;

ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOPAMINE; GENETIC PREDISPOSITION TO DISEASE; GLUTAMINE; MICE; MODELS, GENETIC; SCHIZOPHRENIA;

EID: 33745473238     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2006.02.024     Document Type: Review

References (133)

1. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L.S., et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 97 (2000) 8104-8109
2. Akahane A., Kunugi H., Tanaka H., and Nanko S. Association analysis of polymorphic CGG repeat in 5' UTR of the reelin and VLDLR genes with schizophrenia. Schizophr Res 58 (2002) 37-41
3. Akbarian S., Rios M., Liu R.J., Gold S.J., Fong H.F., Zeiler S., et al. Brain-derived neurotrophic factor is essential for opiate-induced plasticity of noradrenergic neurons. J Neurosci 22 (2002) 4153-4162
4. Albert K.A., Hemmings Jr. H.C., Adamo A.I., Potkin S.G., Akbarian S., Sandman C.A., et al. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch Gen Psychiatry 59 (2002) 705-712
5. Anagnostaras S.G., Murphy G.G., Hamilton S.E., Mitchell S.L., Rahnama N.P., Nathanson N.M., et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 6 (2003) 51-58
6. Baik J.H., Picetti R., Saiardi A., Thiriet G., Dierich A., Depaulis A., et al. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 377 (1995) 424-428
7. Barr A.M., Lehmann-Masten V., Paulus M., Gainetdinov R.R., Caron M.G., and Geyer M.A. The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice. Neuropsychopharmacology 29 (2004) 221-228
8. Beaulieu J.M., Sotnikova T.D., Marion S., Lefkowitz R.J., Gainetdinov R.R., and Caron M.G. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122 (2005) 261-273
9. Beaulieu J.M., Sotnikova T.D., Yao W.D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A 101 (2004) 5099-5104
10. Bonifacino J.S. Insights into the biogenesis of lysosome-related organelles from the study of the hermansky-pudlak syndrome. Ann N Y Acad Sci 1038 (2004) 103-114
11. Brandon N.J., Schurov I., Camargo L.M., Handford E.J., Duran-Jimeni Z.B., Hunt P., et al. Subcellular targeting of DISC1 is dependent on a domain independent from the Nudel binding site. Mol Cell Neurosci 28 (2005) 613-624
12. Callicott J.H., Straub R.E., Pezawas L., Egan M.F., Mattay V.S., Hariri A.R., et al. Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc Natl Acad Sci U S A 102 (2005) 8627-8632
13. Cannon M., Caspi A., Moffitt T.E., Harrington H., Taylor A., Murray R.M., et al. Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder. Results from a longitudinal birth cohort. Arch Gen Psychiatry 59 (2002) 449-456
14. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT). Effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 75 (2004) 807-821
15. Chen J, Wu J, Song J, et al (2005):_Overexpression of human catechol-o-methyltransferase transgene impairs cognitive function in inducible tissue-specific transgenic mice. In: Abstract Viewer and Itinerary Planner. Washington, DC: Society for Neuroscience, 2005 Online, Program No. 1021.14.
16. Chourbaji S., Hellweg R., Brandis D., Zorner B., Zacher C., Lang U.E., et al. Mice with reduced brain-derived neurotrophic factor expression show decreased choline acetyltransferase activity, but regular brain monoamine levels and unaltered emotional behavior. Brain Res Mol Brain Res 121 (2004) 28-36
17. Chowdari K.V., Mirnics K., Semwal P., Wood J., Lawrence E., Bhatia T., et al. Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum Mol Genet 11 (2002) 1373-1380
18. Costa E., Davis J., Pesold C., Tueting P., and Guidotti A. The heterozygote reeler mouse as a model for the development of a new generation of antipsychotics. Curr Opin Pharmacol 2 (2002) 56-62
19. Dalley J.W., Cardinal R.N., and Robbins T.W. Prefrontal executive and cognitive functions in rodents. Neural and neurochemical substrates. Neurosci Biobehav Rev 28 (2004) 771-784
20. Daniels J., Williams J., Asherson P., McGuffin P., and Owen M. No association between schizophrenia and polymorphisms within the genes for debrisoquine 4-hydroxylase (CYP2D6) and the dopamine transporter (DAT). Am J Med Genet 60 (1995) 85-87
21. De Luca V., Wong A.H., Muller D.J., Wong G.W., Tyndale R.F., and Kennedy J.L. Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients. Neuropsychopharmacology 29 (2004) 1522-1526
22. Duncan G.E., Moy S.S., Perez A., Eddy D.M., Zinzow W.M., Lieberman J.A., et al. Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav Brain Res 153 (2004) 507-519
23. Eastwood S.L., Burnet P.W., and Harrison P.J. Decreased hippocampal expression of the susceptibility gene PPP3CC and other calcineurin subunits in schizophrenia. Biol Psychiatry 57 (2005) 702-710
24. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 98 (2001) 6917-6922
25. Egan M.F., Weinberger D.R., and Lu B. Schizophrenia, III. Brain-derived neurotropic factor and genetic risk. Am J Psychiatry 160 (2003) 1242
26. Ekelund J., Hennah W., Hiekkalinna T., Parker A., Meyer J., Lonnqvist J., et al. Replication of 1q42 linkage in Finnish schizophrenia pedigrees. Mol Psychiatry 9 (2004) 1037-1041
27. Ellenbroek B.A. Treatment of schizophrenia. A clinical and preclinical evaluation of neuroleptic drugs. Pharmacol Ther 57 (1993) 1-78
28. Ellenbroek B.A. Animal models in the genomic era. Possibilities and limitations with special emphasis on schizophrenia. Behav Pharmacol 14 (2003) 409-417
29. Erbel-Sieler C., Dudley C., Zhou Y., Wu X., Estill S.J., Han T., et al. Behavioral and regulatory abnormalities in mice deficient in the NPAS1 and NPAS3 transcription factors. Proc Natl Acad Sci U S A 101 (2004) 13648-13653
30. Fienberg A.A., and Greengard P. The DARPP-32 knockout mouse. Brain Res Brain Res Rev 31 (2000) 313-319
31. Fienberg A.A., Hiroi N., Mermelstein P.G., Song W., Snyder G.L., Nishi A., et al. DARPP-32. Regulator of the efficacy of dopaminergic neurotransmission. Science 281 (1998) 838-842
32. Flores G., Alquicer G., Silva-Gomez A.B., Zaldivar G., Stewart J., Quirion R., et al. Alterations in dendritic morphology of prefrontal cortical and nucleus accumbens neurons in post-pubertal rats after neonatal excitotoxic lesions of the ventral hippocampus. Neuroscience 133 (2005) 463-470
33. Fradley R.L., O'Meara G.F., Newman R.J., Andrieux A., Job D., and Reynolds D.S. STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav Brain Res 163 (2005) 257-264
34. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., Olincy A., Davis A., et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A 94 (1997) 587-592
35. Gainetdinov R.R., and Caron M.G. An animal model of attention deficit hyperactivity disorder. Mol Med Today 6 (2000) 43-44
36. Gainetdinov R.R., Mohn A.R., and Caron M.G. Genetic animal models. Focus on schizophrenia. Trends Neurosci 24 (2001) 527-533
37. Gerber D.J., Hall D., Miyakawa T., Demars S., Gogos J.A., Karayiorgou M., et al. Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. Proc Natl Acad Sci U S A 100 (2003) 8993-8998
38. Gerber D.J., Sotnikova T.D., Gainetdinov R.R., Huang S.Y., Caron M.G., and Tonegawa S. Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci U S A 98 (2001) 15312-15317
39. Geyer M.A., McIlwain K.L., and Paylor R. Mouse genetic models for prepulse inhibition. An early review. Mol Psychiatry 7 (2002) 1039-1053
40. Giros B., Jaber M., Jones S.R., Wightman R.M., and Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379 (1996) 606-612
41. Gogos J.A., Morgan M., Luine V., Santha M., Ogawa S., Pfaff D., et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci U S A 95 (1998) 9991-9996
42. Gogos J.A., Santha M., Takacs Z., Beck K.D., Luine V., Lucas L.R., et al. The gene encoding proline dehydrogenase modulates sensorimotor gating in mice. Nat Genet 21 (1999) 434-439
43. Gold S.J., Ni Y.G., Dohlman H.G., and Nestler E.J. Regulators of G-protein signaling (RGS) proteins. Region-specific expression of nine subtypes in rat brain. J Neurosci 17 (1997) 8024-8037
44. Goldberg T.E., Torrey E.F., Gold J.M., Bigelow L.B., Ragland R.D., Taylor E., et al. Genetic risk of neuropsychological impairment in schizophrenia. A study of monozygotic twins discordant and concordant for the disorder. Schizophr Res 17 (1995) 77-84
45. Goldberg T.E., and Weinberger D.R. Genes and the parsing of cognitive processes. Trends Cogn Sci 8 (2004) 325-335
46. Gorski J.A., Balogh S.A., Wehner J.M., and Jones K.R. Learning deficits in forebrain-restricted brain-derived neurotrophic factor mutant mice. Neuroscience 121 (2003) 341-354
47. Grillet N., Pattyn A., Contet C., Kieffer B.L., Goridis C., and Brunet J.F. Generation and characterization of Rgs4 mutant mice. Mol Cell Biol 25 (2005) 4221-4228
48. Gu Z., Jiang Q., Fu A.K., Ip N.Y., and Yan Z. Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex. J Neurosci 25 (2005) 4974-4984
49. Guidotti A., Auta J., Davis J.M., Di-Giorgi-Gerevini V., Dwivedi Y., Grayson D.R., et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder. A postmortem brain study. Arch Gen Psychiatry 57 (2000) 1061-1069
50. Harrison P.J., and Owen M.J. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 361 (2003) 417-419
51. Harrison P.J., and Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology. On the matter of their convergence. Mol Psychiatry 10 (2005) 40-68 image 5
52. Hashimoto R., Straub R.E., Weickert C.S., Hyde T.M., Kleinman J.E., and Weinberger D.R. Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia. Mol Psychiatry 9 (2004) 299-307
53. Hashimoto T., Bergen S.E., Nguyen Q.L., Xu B., Monteggia L.M., Pierri J.N., et al. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci 25 (2005) 372-383
54. Heresco-Levy U., Ermilov M., Lichtenberg P., Bar G., and Javitt D.C. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 55 (2004) 165-171
55. Hietala J., Syvalahti E., Vuorio K., Nagren K., Lehikoinen P., Ruotsalainen U., et al. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 51 (1994) 116-123
56. Hodgkinson C.A., Goldman D., Jaeger J., Persaud S., Kane J.M., Lipsky R.H., et al. Disrupted in schizophrenia 1 (DISC1). Association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am J Hum Genet 75 (2004) 862-872
57. Huotari M., Gogos J.A., Karayiorgou M., Koponen O., Forsberg M., Raasmaja A., et al. Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur J Neurosci 15 (2002) 246-256
58. Impagnatiello F., Guidotti A.R., Pesold C., Dwivedi Y., Caruncho H., Pisu M.G., et al. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci U S A 95 (1998) 15718-15723
59. Jones E.G. Cortical development and neuropathology in schizophrenia. Ciba Found Symp 193 (1995) 277-295
60. Kamnasaran D., Muir W.J., Ferguson-Smith M.A., and Cox D.W. Disruption of the neuronal PAS3 gene in a family affected with schizophrenia. J Med Genet 40 (2003) 325-332
61. Karayiorgou M., and Gogos J.A. Genes for schizophrenia. Lancet 361 (2003) 1828-1829 author reply 1829-1830
62. Kendler K.S. Hierarchy and heritability. The role of diagnosis and modeling in psychiatric genetics. Am J Psychiatry 159 (2002) 515-518
63. Kernie S.G., Liebl D.J., and Parada L.F. BDNF regulates eating behavior and locomotor activity in mice. EMBO J 19 (2000) 1290-1300
64. Kirov G., O'Donovan M.C., and Owen M.J. Finding schizophrenia genes. J Clin Invest 115 (2005) 1440-1448
65. Knable M.B., Barci B.M., Webster M.J., Meador-Woodruff J., and Torrey E.F. Molecular abnormalities of the hippocampus in severe psychiatric illness. Postmortem findings from the Stanley Neuropathology Consortium. Mol Psychiatry 9 (2004) 609-620 544
66. Kohn Y., Danilovich E., Filon D., Oppenheim A., Karni O., Kanyas K., et al. Linkage disequlibrium in the DTNBP1 (dysbindin) gene region and on chromosome 1p36 among psychotic patients from a genetic isolate in Israel. Findings from identity by descent haplotype sharing analysis. Am J Med Genet B Neuropsychiatr Genet 128 (2004) 65-70
67. Koizumi H., Yamaguchi N., Hattori M., Ishikawa T.O., Aoki J., Taketo M.M., et al. Targeted disruption of intracellular type I platelet activating factor-acetylhydrolase catalytic subunits causes severe impairment in spermatogenesis. J Biol Chem 278 (2003) 12489-12494
68. Kojima H., Ohmori O., Shinkai T., Terao T., Suzuki T., and Abe K. Dopamine D1 receptor gene polymorphism and schizophrenia in Japan. Am J Med Genet 88 (1999) 116-119
69. Krystal J.H., D'Souza D.C., Mathalon D., Perry E., Belger A., and Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia. Toward a paradigm shift in medication development. Psychopharmacology (Berl) 169 (2003) 215-233
70. Lavin A., Moore H.M., and Grace A.A. Prenatal disruption of neocortical development alters prefrontal cortical neuron responses to dopamine in adult rats. Neuropsychopharmacology 30 (2005) 1426-1435
71. Law AJ, Lipska BK, Weickert CS, Hyde TM, Straub RE, Hashimoto R, et al (in press): Neuregulin 1 (Nrg1) Transcripts Are Differentially Expressed In Schizophrenia And Regulated By 5' SNPs Associated With The Disease. Proc Natl Acad Sci USA.
72. Li C.H., Liao H.M., and Chen C.H. Identification of molecular variants at the promoter region of the human alpha 7 neuronal nicotinic acetylcholine receptor subunit gene but lack of association with schizophrenia. Neurosci Lett 372 (2004) 1-5
73. Li T., Stefansson H., Gudfinnsson E., Cai G., Liu X., Murray R.M., et al. Identification of a novel neuregulin 1 at-risk haplotype in Han schizophrenia Chinese patients, but no association with the Icelandic/Scottish risk haplotype. Mol Psychiatry 9 (2004) 698-704
74. Li W., Zhang Q., Oiso N., Novak E.K., Gautam R., O'Brien E.P., et al. Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Nat Genet 35 (2003) 84-89
75. Lindgren N., Usiello A., Goiny M., Haycock J., Erbs E., Greengard P., et al. Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites. Proc Natl Acad Sci U S A 100 (2003) 4305-4309
76. Lipska B.K., Chrapusta S.J., Egan M.F., and Weinberger D.R. Neonatal excitotoxic ventral hippocampal damage alters dopamine response to mild repeated stress and to chronic haloperidol. Synapse 20 (1995) 125-130
77. Lipska B.K., Halim N.D., Segal P.N., and Weinberger D.R. Effects of reversible inactivation of the neonatal ventral hippocampus on behavior in the adult rat. J Neurosci 22 (2002) 2835-2842
78. Lipska B.K., and Weinberger D.R. Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Brain Res Dev Brain Res 75 (1993) 213-222
79. Lipska B.K., and Weinberger D.R. To model a psychiatric disorder in animals. Schizophrenia as a reality test. Neuropsychopharmacology 23 (2000) 223-239
80. Lipska B.K., and Weinberger D.R. A neurodevelopmental model of schizophrenia. Neonatal disconnection of the hippocampus. Neurotox Res 4 (2002) 469-475
81. Lyons W.E., Mamounas L.A., Ricaurte G.A., Coppola V., Reid S.W., Bora S.H., et al. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci U S A 96 (1999) 15239-15244
82. Meador-Woodruff J.H., and Healy D.J. Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev 31 (2000) 288-294
83. Mello C.C., and Conte Jr. D. Revealing the world of RNA interference. Nature 431 (2004) 338-342
84. Meyer J., Ortega G., Schraut K., Nurnberg G., Ruschendorf F., Saar K., et al. Exclusion of the neuronal nicotinic acetylcholine receptor alpha7 subunit gene as a candidate for catatonic schizophrenia in a large family supporting the chromosome 15q13-22 locus. Mol Psychiatry 7 (2002) 220-223
85. Millar J.K., Wilson-Annan J.C., Anderson S., Christie S., Taylor M.S., Semple C.A., et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet 9 (2000) 1415-1423
86. Mirnics K., Middleton F.A., Stanwood G.D., Lewis D.A., and Levitt P. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry 6 (2001) 293-301
87. Miyakawa T., Leiter L.M., Gerber D.J., Gainetdinov R.R., Sotnikova T.D., Zeng H., et al. Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci U S A 100 (2003) 8987-8992
88. Miyakawa T., Yamada M., Duttaroy A., and Wess J. Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J Neurosci 21 (2001) 5239-5250
89. Moghaddam B., Adams B., Verma A., and Daly D. Activation of glutamatergic neurotransmission by ketamine. A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17 (1997) 2921-2927
90. Mohn A.R., Gainetdinov R.R., Caron M.G., and Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98 (1999) 427-436
91. Monteggia L.M., Barrot M., Powell C.M., Berton O., Galanis V., Gemelli T., et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci U S A 101 (2004) 10827-10832
92. Morley B.J., and Rodriguez-Sierra J.F. A phenotype for the alpha 7 nicotinic acetylcholine receptor null mutant. Brain Res 1023 (2004) 41-47
93. Morris J.A., Kandpal G., Ma L., and Austin C.P. DISC1 (Disrupted-In-Schizophrenia 1) is a centrosome-associated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL. Regulation and loss of interaction with mutation. Hum Mol Genet 12 (2003) 1591-1608
94. Niemi L.T., Suvisaari J.M., Haukka J.K., and Lonnqvist J.K. Childhood predictors of future psychiatric morbidity in offspring of mothers with psychotic disorder. Results from the Helsinki High-Risk Study. Br J Psychiatry 186 (2005) 108-114
95. O'Donovan M.C., Williams N.M., and Owen M.J. Recent advances in the genetics of schizophrenia. Hum Mol Genet 12 Spec No 2 (2003) R125-R133
96. Ohshima T., Ward J.M., Huh C.G., Longenecker G., Veeranna, Pant H.C., et al. Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci U S A 93 (1996) 11173-11178
97. Ozeki Y., Tomoda T., Kleiderlein J., Kamiya A., Bord L., Fujii K., et al. Disrupted-in-Schizophrenia-1 (DISC-1). Mutant truncation prevents binding to NudE-like (NUDEL) and inhibits neurite outgrowth. Proc Natl Acad Sci U S A 100 (2003) 289-294
98. Paterlini M., Zakharenko S.S., Lai W.S., Qin J., Zhang H., Mukai J., et al. Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. Nat Neurosci 8 (2005) 1586-1594
99. Paylor R., Zhao Y., Libbey M., Westphal H., and Crawley J.N. Learning impairments and motor dysfunctions in adult Lhx5-deficient mice displaying hippocampal disorganization. Physiol Behav 73 (2001) 781-792
100. Petryshen T.L., Middleton F.A., Kirby A., Aldinger K.A., Purcell S., Tahl A.R., et al. Support for involvement of neuregulin 1 in schizophrenia pathophysiology. Mol Psychiatry 10 (2005) 366-374 328
101. Protais P., Costentin J., and Schwartz J.C. Climbing behavior induced by apomorphine in mice. A simple test for the study of dopamine receptors in striatum. Psychopharmacology (Berl) 50 (1976) 1-6
102. Rakhilin S.V., Olson P.A., Nishi A., Starkova N.N., Fienberg A.A., Nairn A.C., et al. A network of control mediated by regulator of calcium/calmodulin-dependent signaling. Science 306 (2004) 698-701
103. Ralph R.J., Paulus M.P., Fumagalli F., Caron M.G., and Geyer M.A. Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice. Differential effects of D1 and D2 receptor antagonists. J Neurosci 21 (2001) 305-313
104. Ralph-Williams R.J., Lehmann-Masten V., Otero-Corchon V., Low M.J., and Geyer M.A. Differential effects of direct and indirect dopamine agonists on prepulse inhibition. A study in D1 and D2 receptor knock-out mice. J Neurosci 22 (2002) 9604-9611
105. Randrup A., and Munkvad I. Pharmacology and physiology of stereotyped behavior. J Psychiatr Res 11 (1974) 1-10
106. Schwab S.G., Knapp M., Mondabon S., Hallmayer J., Borrmann-Hassenbach M., Albus M., et al. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am J Hum Genet 72 (2003) 185-190
107. Selemon L.D. Increased cortical neuronal density in schizophrenia. Am J Psychiatry 161 (2004) 1564
108. Smolka M.N., Schumann G., Wrase J., Grusser S.M., Flor H., Mann K., et al. Catechol-O-methyltransferase val158met genotype affects processing of emotional stimuli in the amygdala and prefrontal cortex. J Neurosci 25 (2005) 836-842
109. Snyder S.H. Catecholamines in the brain as mediators of amphetamine psychosis. Arch Gen Psychiatry 27 (1972) 169-179
110. Sokolov B.P. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of "neuroleptic-free" schizophrenics. Evidence on reversible up-regulation by typical neuroleptics. J Neurochem 71 (1998) 2454-2464
111. Stefansson H., Sarginson J., Kong A., Yates P., Steinthorsdottir V., Gudfinnsson E., et al. Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet 72 (2003) 83-87
112. Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71 (2002) 877-892
113. Stefansson H., Steinthorsdottir V., Thorgeirsson T.E., Gulcher J.R., and Stefansson K. Neuregulin 1 and schizophrenia. Ann Med 36 (2004) 62-71
114. Straub R.E., Jiang Y., MacLean C.J., Ma Y., Webb B.T., Myakishev M.V., et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 71 (2002) 337-348
115. Svenningsson P., Tzavara E.T., Carruthers R., Rachleff I., Wattler S., Nehls M., et al. Diverse psychotomimetics act through a common signaling pathway. Science 302 (2003) 1412-1415
116. Swerdlow N.R., Braff D.L., Taaid N., and Geyer M.A. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 51 (1994) 139-154
117. Talbot K., Eidem W.L., Tinsley C.L., Benson M.A., Thompson E.W., Smith R.J., et al. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 113 (2004) 1353-1363
118. Toyoda H., Takahata R., Inayama Y., Sakai J., Matsumura H., Yoneda H., et al. Effect of antipsychotic drugs on the gene expression of NMDA receptor subunits in rats. Neurochem Res 22 (1997) 249-252
119. Tsai G., and Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42 (2002) 165-179
120. Tsai G.E., Yang P., Chung L.C., Tsai I.C., Tsai C.W., and Coyle J.T. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 156 (1999) 1822-1825
121. Usiello A., Baik J.H., Rouge-Pont F., Picetti R., Dierich A., Le Meur M., et al. Distinct functions of the two isoforms of dopamine D2 receptors. Nature 408 (2000) 199-203
122. Vicente A.M., Macciardi F., Verga M., Bassett A.S., Honer W.G., Bean G., et al. NCAM and schizophrenia. Genetic studies. Mol Psychiatry 2 (1997) 65-69
123. Weickert C.S., Ligons D.L., Romanczyk T., Ungaro G., Hyde T.M., Herman M.M., et al. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol Psychiatry 10 (2005) 637-650
124. Weickert C.S., Straub R.E., McClintock B.W., Matsumoto M., Hashimoto R., Hyde J.M., et al. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch Gen Psychiatry 61 (2004) 544-555
125. Weinberger D.R. From neuropathology to neurodevelopment. Lancet 346 (1995) 552-557
126. Weinberger D.R., Egan M.F., Bertolino A., Callicott J.H., Mattay V.S., Lipska B.K., et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 50 (2001) 825-844
127. Weinberger D.R., and Lipska B.K. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia. A search for common ground. Schizophr Res 16 (1995) 87-110
128. West A.R., Floresco S.B., Charara A., Rosenkranz J.A., and Grace A.A. Electrophysiological interactions between striatal glutamatergic and dopaminergic systems. Ann N Y Acad Sci 1003 (2003) 53-74
129. Wood G.K., Tomasiewicz H., Rutishauser U., Magnuson T., Quirion R., Rochford J., et al. NCAM-180 knockout mice display increased lateral ventricle size and reduced prepulse inhibition of startle. Neuroreport 9 (1998) 461-466
130. Xu M., Guo Y., Vorhees C.V., and Zhang J. Behavioral responses to cocaine and amphetamine administration in mice lacking the dopamine D1 receptor. Brain Res 852 (2000) 198-207
131. Xu M., Moratalla R., Gold L.H., Hiroi N., Koob G.F., Graybiel A.M., et al. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell 79 (1994) 729-742
132. Yu J.Y., DeRuiter S.L., and Turner D.L. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci U S A 99 (2002) 6047-6052
133. Zhuang X., Oosting R.S., Jones S.R., Gainetdinov R.R., Miller G.W., Caron M.G., et al. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci U S A 98 (2001) 1982-1987